IP Library Granted Patent US 8,524,496
Granted Patent B2
US 8,524,496 · App. 13/061,538 · Granted Sep 3, 2013

Adherent cells from placenta tissue and use thereof in therapy

Inventors: Moran Meiron (Zikhron-Yaakov, IL); Amir Toren (Zikhron-Yaakov, IL); Rachel Ofir (Mitzpe Adi, IL); Nirit Drori-Carmi (Doar-Na Hof HaCarmel, IL)
Assignee: Pluristem Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,496
App. No.
13/061,538
Granted
Sep 3, 2013
Kind
B2
Abstract

A method of culturing adherent cells from a placenta or adipose tissue is disclosed. The method comprising culturing the adherent cells from the placenta or adipose tissue under 3 dimensional (3D) culturing conditions which allow cell expansion, the conditions comprising perfusion.

Claims (12)

1. A method of culturing adherent cells from a placenta or adipose tissue, the method comprising culturing the adherent cells from the placenta or adipose tissue under three-dimensional (3D) culturing conditions which allow cell expansion, said conditions comprising perfusion, wherein the rate of said perfusion is adjusted according to the glucose concentration of the culture medium, and wherein said culture medium is changed at a glucose concentration of about 500 mg/L to about 600 mg/L.

2. The method of claim 1 , wherein said 3D culturing conditions:

(a) comprise a 3D bioreactor; or

(b) comprise an adherent material selected from the group consisting of glass. plastic, polyester, and polypropylene, polystyrene, dextran and collagen; or

(c) are effected for at least 3 days; or

(d) comprise a combination thereof.

3. The method of claim 1 , wherein said culturing of said cells is effected until at least 10% of said cells are proliferating.

4. The method of claim 1 , wherein said 3D culturing conditions comprise:

(i) culturing said adherent cells in a bioreactor having a cylinder packed bed and the culture medium is flown through the packed bed; or

(ii) culturing said adherent cells in a growth phase maintaining working volume of at least about 1,500 mL; or

(iii) seeding said adherent cells at a seeding concentration of at least about 0.1×10 6 cell/ml; or

(iv) culturing said adherent cells in a bioreactor having a carrier of at least 30 grams weight.

Assignments (2)
CHANGE OF NAME Recorded Dec 30, 2022
From: PLURISTEM LTD.
To: PLURI BIOTECH LTD.
Reel/Frame 062247/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2011
From: MEIRON, MORAN; TOREN, AMIR; OFIR, RACHEL; DRORI-CARMI, NIRIT
To: PLURISTEM LTD.
Reel/Frame 026564/0362 →
Continuity (3)
Provisional Application 61136375 · Sep 2, 2008
Provisional Application 61202050 · Jan 23, 2009
Related Publication 20110256159A1 · Oct 20, 2011